PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.\', \'Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Cairo, Egypt; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.\', \'Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Cairo, Egypt.\', \'Department of Pulmonary Medicine, Abbassia Chest Hospital, MOH, Cairo, Egypt.\', \'Department of Tropical Medicine and Infectious Disease, Imbaba Fever Hospital, MOH, Cairo, Egypt.\', \'Microbiology Department, College of Medicine, Taif University, P.O. Box 1109, Taif, 21944, Saudi Arabia. Electronic address: asa@tu.edu.sa.\', \'Department of Clinical and Chemical Pathology, Elsahel Teaching Hospital, MOH, Cairo, Egypt.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0042-6822(21)00174-410.1016/j.virol.2021.08.012
?:hasPublicationType
?:journal
  • Virology
is ?:pmid of
?:pmid
?:pmid
  • 34478955
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.728
?:rankingScore_hIndex
  • 159
is ?:relation_isRelatedTo_publication of
?:title
  • Upregulation of FOXP3 is associated with severity of hypoxia and poor outcomes in COVID-19 patients.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all